Results 161 to 170 of about 39,266 (270)

The sliding cupping therapy as an alternative strategy for treating plaque psoriasis: A randomized controlled trial. [PDF]

Medicine (Baltimore)
Liu J, Guo S, Tan J, Miao M, Shi Y, Tan C, Wei Y.   +6 more
europepmc   +1 more source

Plaque Psoriasis

International Journal of Clinical & Medical Imaging, 2015
openaire   +1 more source

Bispecific Dual‐Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients

Journal of Cutaneous Pathology, Volume 53, Issue 5, Page 422-426, May 2026.
ABSTRACT Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T‐lymphocyte‐associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration‐resistant prostate carcinoma.
Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya, Doina Ivan, Victor G. Prieto, Jonathan L. Curry   +5 more
wiley   +1 more source

Secukinumab-Induced Delayed Behçet-Like Reaction in a Patient with Plaque Psoriasis: A Case Report. [PDF]

Clin Cosmet Investig Dermatol
Wei Y, Zhang P, Chuan J, Ye J, Liu T.
europepmc   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, Volume 6, Issue 4, April 2026.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Emergence of Vitiligo during Treatment with Risankizumab-Rzaa for Plaque Psoriasis: A Case Report. [PDF]

Case Rep Dermatol
Thomas KV, Tran JM, Cotter LM.
europepmc   +1 more source

Pharmacokinetic, Safety, and Immunogenicity Similarity of High‐ and Low‐Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab‐Atto

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
Consistent with previously demonstrated similarity of biosimilar ABP 501 (adalimumab‐atto) with adalimumab reference product, this study in healthy adults demonstrates the pharmacokinetic, safety, and immunogenicity similarity of a high‐concentration formulation (100 mg/mL) of ABP 501 with the original 50mg/mL formulation.
Vincent Chow, Muhan Zhou, Daniel T. Mytych, Alexander Colbert, Mieke Jill Miller, Iwona Wala, Ahad Sabet, Waldemar Radziszewski   +7 more
wiley   +1 more source

Chronic Plaque Psoriasis With Persistent Facial Involvement Successfully Treated With Risankizumab: A Case Report. [PDF]

Cureus
AlQusaimi R, AlRujaib F, AlSharhan F, Alassaf S, Khoursheed L, Abdulrahman F, AlAwadhi D.   +6 more
europepmc   +1 more source

Impact of Treatment Interruption on the Effectiveness of Interleukin (IL)-17A Inhibitors in Plaque Psoriasis: A Retrospective Analysis

International Journal of General Medicine
Jin Jiang,1 Meihua Zhang,2 Mi Li1 1Department of Dermatology, Liyang People’s Hospital, Liyang, People’s Republic of China; 2Department of Dermatology, Jiangsu Provincial People’s Hospital, Nanjing, People’s Republic of ChinaCorrespondence: Mi Li ...
Jiang J, Zhang M, Li M
doaj  

Baseline Clinical and Metabolic Predictors of 52-Week Durability of Secukinumab Response in Moderate-to-Severe Plaque Psoriasis. [PDF]

Clin Cosmet Investig Dermatol
Wang J, Li P.
europepmc   +1 more source